Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily continuous Tobramycin Inhalation Powder vs twice-daily cyclic dosing in cystic fibrosis
2016-004318-82Phase 4
- Sponsor
- Novartis
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tobramycin in cystic fibrosis (CF) and Pseudomonas aeruginosa airway infection (2 arms), sponsored by Novartis. Primary endpoint: Change from baseline in FEV1 percent predicted at Day 168.
02
Drugs
tobramycin
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa airway infection
Beyond the preview
Go deeper on 2016-004318-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004318-82.